Development, characterization and biological in vitro assays of paclitaxel-loaded PCL polymeric nanoparticles

Author(s)

Abriata, Juliana Palma ^[1] ; Turatti, Roger Casanova ^[1] ; Luiz, Marcela Tavares ^[1] ; Raspantini, Giovanni Loureiro ^[1] ; Tofani, Larissa Bueno ^[1] ; Ferraz do Amaral, Robson Luis ^[1] ; Swiech, Kamilla ^[1] ; Marcato, Priscyla Daniely ^[1] ; Marchetti, Juliana Maldonado ^[1]

Affiliation

^[1] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Ribeirao Preto, SP - Brazil

• Document type: Journal article
• Source: Materials Science & Engineering C-Materials for Biological Applications; v. 96, p. 347-355, MAR 2019.
• Web of Science Citations: 4

Abstract

Adenocarcinoma is the most lethal gynecologic tumor and treatment usually consists in surgery followed by chemotherapy. However, the chemotherapy benefits are eventually limited due to drug toxicity to normal tissues and cells, which cause several and harsh side effects. Paclitaxel (PCX) is the drug of first choice for ovarian cancer treatment, but it has low aqueous solubility, which reduces its bioavailability. Thus, in the commercial drug, Taxol (R), PCX is solubilized in a mixture of toxic surfactants. The development of drug nanocarriers has been investigated to promote the reduction of toxic effects and increase the safety and therapeutic efficacy of PCX. The aim of this work was the development and characterization of PCX loaded nanoparticles (PNPCX) and evaluation of in vitro efficacy of developed system using adenocarcinoma cell line. The nanocarrier was successfully obtained using nanoprecipitation technique. The results showed that the PNPCX-A had a particle size distribution around 140 nm and polydispersity index smaller than 0.1, with high PCX encapsulation efficiency. The results obtained were suitable for the intravenous administration route and promotion of passive targeting in the tumor microenvironment. The in vitro cytotoxicity assays of SKOV-3 cell line demonstrated that PNPCX-A was able to release PCX and reduce cell viability. The flow cytometry assays first reported that a nanostructured system with such composition (PNPCX-A) presented a time dependent cellular uptake, showing the ability of nanocarrier to be internalized. PNPCX-A present a distinguish potential for ovarian cancer therapy optimization. In vivo studies are needed to confirm the in vitro results and provide additional data regarding safety and efficacy of ovarian cancer treatment. (AU)

• FAPESP's process: 14/08462-6 - Development and characterization of nanoparticles with polycaprolactone containing paclitaxel targeted with bevacizumab for optimization of ovarian cancer therapy
• Grantee: Juliana Maldonado Marchetti
• Support type: Regular Research Grants
• FAPESP's process: 13/22747-0 - Development and characterization of nanoparticles with polycaprolactone containing paclitaxel targeted with bevacizumab for optimization of ovarian cancer therapy
• Grantee: Juliana Palma Abriata
• Support type: Scholarships in Brazil - Doctorate